Healthequity, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Michael Henry Fiore, EVP, CHIEF COMMERCIAL OFFICER of Healthequity, Inc., sold 2,354 shares of common stock on July 10, 2026 for $95.00 per share.
NASDAQ
Michael Gathright, Chief Customer Officer of Healthequity, Inc., reported a transaction in 2,270 shares of common stock on July 9, 2026.
NASDAQ
Stephen Neeleman, Founder and Vice Chairman of HealthEquity, Inc., reported a transaction involving the sale of common stock.
NASDAQ
HealthEquity EVP & CFO James M. Lucania reported a sale of 2,839 shares of common stock on July 8, 2026.
NASDAQ
HealthEquity Inc. executive Delano Ladd reported a sale of 1,087 shares of common stock on July 8, 2026, for $95.08 per share.
NASDAQ
HealthEquity, Inc. reports a Form 4 filing detailing stock transactions by President and CEO Scott Cutler.
NASDAQ
Healthequity, Inc. executive Michael Fiore sold 2,045 shares of common stock for $95.0831 per share.
NASDAQ
HealthEquity Inc. executive Michael Fiore reported a transaction involving the sale of common stock, executed under a pre-arranged trading plan.
NASDAQ
HealthEquity, Inc. reports a Form 4 filing detailing William Gassen's acquisition of 2,877 shares of common stock.
NASDAQ
HealthEquity, Inc. Director Rajesh Natarajan acquired 2,877 shares of common stock on June 25, 2026, as reported in a Form 4 filing.
NASDAQ
HealthEquity, Inc. Director Stuart B. Parker acquired 2,877 shares of common stock through restricted stock units.
NASDAQ
HealthEquity Director Gayle Furgurson Wellborn acquired 2,877 shares of common stock.
NASDAQ
HealthEquity, Inc. Director Adrian T. Dillon acquired 2,877 shares of common stock on June 25, 2026.
NASDAQ
Evelyn S. Dilsaver, a Director at HealthEquity, Inc., acquired 2,877 shares of common stock on June 25, 2026.
NASDAQ
HealthEquity, Inc. Director Robert W. Selander acquired 2,877 shares of common stock on June 25, 2026, increasing his beneficial ownership.
NASDAQ
HealthEquity Inc. executive Michael Fiore reported a sale of 3,142 shares of common stock, executed under a pre-arranged 10b5-1 trading plan.
NASDAQ
HealthEquity director Gayle Wellborn exercised options and sold 2,439 shares of common stock under a pre-arranged 10b5-1 plan.
NASDAQ
HealthEquity, Inc. EVP and General Counsel Delano Ladd sold 7,500 shares of common stock via a Rule 10b5-1 trading plan.
NASDAQ
Stephen Neeleman, Founder and Vice Chairman of HealthEquity, Inc., reported a series of transactions involving common stock and stock options.
NASDAQ
HealthEquity Inc. EVP, General Counsel Ladd Delano reported a sale of 2,481 shares of common stock on April 6, 2026.
NASDAQ
Michael Fiore, EVP and Chief Commercial Officer of HealthEquity, Inc., reported a sale of 3,378 shares of common stock.
NASDAQ
HealthEquity, Inc. EVP, Chief Technology Officer Elimelech Rosner reported a sale of 4,768 shares of common stock on April 6, 2026.
NASDAQ
Form 4: HealthEquity CFO Sells Shares
HealthEquity's EVP & CFO, James M. Lucania, reported a sale of 4,393 shares of common stock on April 6, 2026.
NASDAQ
HealthEquity, Inc. President and CEO Scott Cutler reported a transaction involving the acquisition of common stock.
NASDAQ
HealthEquity Inc. EVP, General Counsel Delano Ladd reported a sale of 7,726 shares of common stock on March 31, 2026.
NASDAQ
Stephen Neeleman, Founder and Vice Chairman of HealthEquity, Inc., reported transactions involving common stock and stock options.
NASDAQ
HealthEquity Inc. EVP, Chief Technology Officer Elimelech Rosner reported a sale of 18,010 common shares on March 31, 2026.
NASDAQ
HealthEquity's EVP and General Counsel, Delano Ladd, increased direct beneficial ownership through the vesting and grant of restricted stock units.
NASDAQ
HealthEquity's Chief Customer Officer, Michael Gathright, was granted 15,157 restricted stock units, aligning his interests with shareholders.
NASDAQ
Stephen Neeleman, Founder and Vice Chairman of HealthEquity, reported the acquisition of common stock through restricted stock units and disclosed existing stock options.